If BPC-157 was purchased today, the patent would likely expire in 2033 before the phase 1-2-3 trials would be completed, at which point all the generic manufacturers would be able to push the product on the back of all the hard work a pharmaceutical company can do (Im not sure if FDA approval would push the expiration of the patent back, but even then it would not be so financial lucrative)
This is also the reason for the amber colour of the packaging, to better preserve all the goodness inside
[DOI] [PMC free article] [PubMed] [Google Scholar] 20
This displaced material may press against nearby nerve roots, causing the characteristic pain, numbness, and weakness associated with disc problems
Below: injectable, IV, and buccal protocols with documented dose ranges, delivery-route trade-offs, and reconstitution math for the full mechanism and age-decline research, see the glutathione peptide page
Johns Wort This herbal supplement can decrease the effectiveness of blood thinners